Many men diagnosed with localized prostate cancer can postpone definitive treatment
without raising their risk of metastasis or death from disease. Active surveillance (AS) is a …

Background Despite the key importance of magnetic resonance imaging (MRI) parameters,
risk classification systems for biochemical recurrence (BCR) in prostate cancer (PCa) …

Prostate cancer (PCa) is the fifth leading cause of cancer related deaths worldwide, in part
due to a lack of molecular stratification tools that can distinguish primary tumours that will …

While radical prostatectomy remains the mainstay of prostate cancer (PCa) treatment, 20 to
40% of patients develop postsurgical biochemical recurrence (BCR). A particularly …

Objectives To compare the performance of the PRECISE scoring system against several
MRI-derived delta-radiomics models for predicting histopathological prostate cancer (PCa) …

Abstract Purpose of Review The goal of this paper was to review the novel treatment
modality of high-intensity transurethral directional ultrasound for prostate cancer. Recent …

PURPOSE The European Organisation for Research and Treatment of Cancer (EORTC) trial
22991 (NCT00021450) showed that 6 months of concomitant and adjuvant androgen …

PURPOSE The Genomic Prostate Score (GPS), performed on biopsy tissue, predicts
adverse outcome in prostate cancer (PCa) and has shown promise for improving patient …

Distinguishing indolent from clinically significant localized prostate cancer is a major clinical
challenge and influences clinical decision-making between treatment and active …

Simple Summary Recurrence and metastatic progression always lead to dismal outcomes in
prostate cancer (PCa). There is no reliable biomarker for the prediction of recurrence and …